-
公开(公告)号:AU2194395A
公开(公告)日:1995-10-17
申请号:AU2194395
申请日:1995-03-23
Applicant: VERTEX PHARMA
Inventor: ZELLE ROBERT EDWARD , HARDING MATTHEW W
IPC: A61K31/4406 , A61K31/4418 , A61K31/445 , A61K31/47 , A61K31/535 , A61P43/00 , C07C271/18 , C07C279/10 , C07C333/04 , C07C335/06 , C07D211/60 , C07D213/30 , C07D213/55 , C07D401/12 , C07D401/14 , C07D213/65 , A61K31/17 , A61K31/27 , A61K31/44 , C07C271/54 , C07C275/34 , C07D215/20
-
公开(公告)号:HUT70259A
公开(公告)日:1995-09-28
申请号:HU9303164
申请日:1992-05-07
Applicant: VERTEX PHARMA
Inventor: HARDING MATTHEW W
-
公开(公告)号:NZ573052A
公开(公告)日:2012-03-30
申请号:NZ57305207
申请日:2007-04-25
Applicant: VERTEX PHARMA
Inventor: RAMACHANDRAN RAVI K , HARDING MATTHEW W , CARON PAUL R , BOTFIELD MARTYN , HARE BRIAN J , BANDARU RAJ , KELLIHER KEVIN M , CORNELL CATHARINE N
Abstract: Disclosed is a method of evaluating a subject, the method comprising: determining the expression levels of the genes in a signature set of genes in the subject, wherein the signature set of genes comprises one or more interferon-sensitive genes(ISG) selected from the group consisting of IFIT1, RSAD2, IFIT2, IFIT6, IFI44, IFIT5, PLSCR1, IFIT3, IFI35, IFITM1, IFITM3, IFI30, IFITM2, GIP2, OAS3, MX1, IFIL44L, IFI27, IFIT2A, PRSAD, or IFITA, wherein the signature set has the following properties: it includes a plurality of genes each of which is differentially expressed as between virally infected individuals and non-infected individuals, and the differential expression is predictive of infection with no more than about 15% false positives; and comparing the expression level of each of the genes in the set from the subject with a reference value, thereby evaluating the subject, wherein the reference value is either: (i) a non-infected reference and wherein differential expression of each of the genes in the signature set of genes indicates a first state, and differential expression of less than all of the genes in the signature set indicates a second state; or (ii) an infected reference and wherein non-differential expression of each of the genes in the signature set of genes indicates a first state, and non-differential expression of less than all of the genes in the signature set indicates a second state, wherein the evaluating occurs prior to, during the course of, or after administering an inhibitor of a viral protease to the subject, and wherein the evaluation of the expression of the genes in a signature set of genes is performed on an isolated sample from the subject.
-
公开(公告)号:ES2311491T3
公开(公告)日:2009-02-16
申请号:ES01111169
申请日:1995-03-23
Applicant: VERTEX PHARMA
Inventor: ZELLE ROBERT EDWARD , HARDING MATTHEW W
IPC: A61K31/4406 , A61K31/4418 , A61K31/445 , A61K31/47 , A61K31/535 , A61P35/00 , A61P43/00 , C07C271/18 , C07C279/10 , C07C333/04 , C07C335/06 , C07D211/60 , C07D213/30 , C07D213/55 , C07D401/12 , C07D401/14
Abstract: Un compuesto de la fórmula (II'') o (III''): (Ver fórmulas) en las que: Y es O o N; donde: cuando Y es O, entonces R1 es un par aislado y R2 se selecciona del grupo que consiste en Ar, alquilo (C1-C6) lineal o ramificado, y alquenilo o alquinilo (C3-C6) lineal o ramificado; cuando Y es N, entonces R1 y R2 se seleccionan independientemente del grupo que consiste en Ar, alquilo (C1-C6) lineal o ramificado y alquenilo o alquinilo (C3-C6) lineal o ramificado; o R1 y R2 se consideran juntos para formar un anillo heterocíclico de 5-6 miembros seleccionado del grupo que consiste en pirrolidina, imidazolidina, pirazolidina, piperidina y piperazina; Ar se selecciona del grupo que consiste en fenilo, 2-piridilo, 3-piridilo, 4-piridilo, indolilo, isoindolilo, quinolinilo, isoquinolinilo, 1,2,3,4-tetrahidroisoquinolinilo y 1,2,3,4-tetrahidroquinolinilo; donde dicho Ar puede contener uno o más sustituyentes que se seleccionan independientemente del grupo que consiste en hidrógeno, hidroxilo, nitro, trifluorometilo, alquilo (C1-C6) lineal o ramificado, O-[alquilo (C1-C6) lineal o ramificado], halógeno, SO3H y NR3R4; donde R3 y R4 se seleccionan independientemente del grupo que consiste en alquilo (C1-C6) lineal o ramificado, alquenilo (C3-C6) lineal o ramificado, hidrógeno y bencilo; o donde R3 y R4 se pueden considerar juntos para formar un anillo heterocíclico de 5-6 miembros; J es hidrógeno, alquilo (C1-C6) lineal o ramificado o alquenilo (C3-C6) lineal o ramificado; y w es 1 ó 2.
-
公开(公告)号:NO20084954L
公开(公告)日:2009-01-22
申请号:NO20084954
申请日:2008-11-25
Applicant: VERTEX PHARMA
Inventor: BOTFIELD MARTYN C , RAMACHANDRAN RAVI K , HARDING MATTHEW W , CARON PAUL R , HARE BRIAN J , BANDARU RAJ , KELLIHER KEVIN M , CORNELL CATHARINE N
IPC: C12Q1/70
-
公开(公告)号:NO20084954A
公开(公告)日:2009-01-22
申请号:NO20084954
申请日:2008-11-25
Applicant: VERTEX PHARMA
Inventor: BOTFIELD MARTYN C , RAMACHANDRAN RAVI K , HARDING MATTHEW W , CARON PAUL R , HARE BRIAN J , BANDARU RAJ , KELLIHER KEVIN M , CORNELL CATHARINE N
IPC: C12Q1/70
CPC classification number: C12Q1/707 , C12Q2545/114
-
公开(公告)号:HU226136B1
公开(公告)日:2008-05-28
申请号:HU9802168
申请日:1995-11-13
Applicant: VERTEX PHARMA
Inventor: HARDING MATTHEW W , ZELLE ROBERT E
IPC: C07C237/00 , C07C237/02 , C07D333/06 , A61K31/00 , A61K31/16 , A61K31/165 , A61K31/395 , A61K31/41 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61P35/00 , C07C231/02 , C07C237/22 , C07C309/51 , C07C309/59 , C07C317/28 , C07C323/41 , C07D213/38 , C07D213/40 , C07D213/50 , C07D213/56 , C07D213/81 , C07D233/54 , C07D233/90 , C07D261/08 , C07D263/32 , C07D271/04 , C07D277/20 , C07D277/22 , C07D277/38 , C07D277/64 , C07D333/36 , C07D521/00
-
公开(公告)号:CZ298586B6
公开(公告)日:2007-11-14
申请号:CZ149197
申请日:1995-11-13
Applicant: VERTEX PHARMA
Inventor: ZELLE ROBERT E , HARDING MATTHEW W
IPC: C07C237/00 , C07C237/02 , C07D333/06 , A61K31/00 , A61K31/16 , A61K31/165 , A61K31/395 , A61K31/41 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61P35/00 , A61P43/00 , C07C231/02 , C07C237/22 , C07C309/51 , C07C309/59 , C07C317/28 , C07C323/41 , C07D213/38 , C07D213/40 , C07D213/50 , C07D213/56 , C07D213/81 , C07D233/54 , C07D233/90 , C07D261/08 , C07D263/32 , C07D271/04 , C07D277/20 , C07D277/22 , C07D277/38 , C07D277/64 , C07D333/36 , C07D521/00
Abstract: Deriváty aminokyselin obecného vzorce I nebo obecného vzorce II, ve kterých J a K znamenají prímou nebo rozvetvenou (C1-C6)-alkylovou skupinu, prípadne substituovanou skupinou Ar; kde každá skupina Ar je nezávisle vybrána ze souboru sestávajícího z fenylové, 2-, 3-, 4-pyridylové a imidazolylové skupiny, pricemž uvedená skupina Ar muže obsahovat jeden nebo více substituentu, které jsou nezávisle vybrány ze souboru sestávajícího z vodíku, hydroxylové skupiny, nitroskupiny, trifluormehtylové skupiny, prímé nebo rozvetvené (C1-C6)-alkylové skupiny, prímé nebo rozvetvené O-(C1-C6)-alkylové skupiny, halogenu, skupiny SO.sub.3.n.H a skupiny NR.sub.3.n.R.sub.4.n.; a každé w znamená 1 nebo 2. Tyto slouceniny udržují, zvyšují nebo obnovují citlivostbunek na terapeutická nebo profylaktická cinidla.Vynález se rovnež týká zpusobu prípravy techto sloucenin a farmaceutických prostredku, které tyto slouceniny obsahují. Slouceniny a farmaceutické prostredky jsou zejména vhodné pro lécení nebo prevenci mnohocetné lékové rezistence.
-
公开(公告)号:CA2650616A1
公开(公告)日:2007-11-08
申请号:CA2650616
申请日:2007-04-25
Applicant: VERTEX PHARMA
Inventor: CORNELL CATHARINE N , BOTFIELD MARTYN C , KELLIHER KEVIN M , BANDARU RAJ , HARE BRIAN J , RAMACHANDRAN RAVI K , CARON PAUL R , HARDING MATTHEW W
-
公开(公告)号:RO121113B1
公开(公告)日:2006-12-29
申请号:RO9700899
申请日:1995-11-13
Applicant: VERTEX PHARMA
Inventor: ZELLE ROBERT E , HARDING MATTHEW W
IPC: C07C237/00 , C07C237/02 , C07D333/06 , A61K31/00 , A61K31/16 , A61K31/165 , A61K31/395 , A61K31/41 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/4418 , A61P35/00 , C07C231/02 , C07C237/22 , C07C309/51 , C07C309/59 , C07C317/28 , C07C323/41 , C07D213/38 , C07D213/40 , C07D213/50 , C07D213/56 , C07D213/81 , C07D233/54 , C07D233/90 , C07D261/08 , C07D263/32 , C07D271/04 , C07D277/20 , C07D277/22 , C07D277/38 , C07D277/64 , C07D333/36 , C07D521/00
Abstract: Prezenta invenţie se referă la derivaţi de aminoacid cu formula (I): în care J şi K sunt un alchil (C1-C6) liniar sau ramificat sau Ar substituit cu alchil (C1-C6) liniar sau ramificat, fiecare Ar este selectat în mod independent din grupul constând din fenil, 2-piridil, 3-piridil, 4-piridilşi imidazolil, care pot menţine, mări sau restabili sensibilitatea celulelor la agenţi terapeutici sau profilactici.
-
-
-
-
-
-
-
-
-